$0.44
(1.43%)
0.90%
Create an alert
Stocks and Shares ISAIDEAYA Biosciences, Inc. is a medicine oncology company. The Company is engaged in the discovery, development, and commercialization of transformative therapies for cancer. Its product candidates focus on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Its product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE161 (PARG), IDE275 (Werner Helicase) and IDE705 (Pol Theta Helicase). Darovasertib is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. IDE397 is an oral small molecule inhibitor of methionine adenosyl transferase 2a (MAT2A). IDE161 is an oral small molecule poly (ADP-ribose) glycohydrolase (PARG) inhibitor. IDE275 is an oral small molecule inhibitor of the helicase domain of the Werner protein (WRN), a RecQ enzyme involved in the maintenance of genome integrity.
Company Information
About this company
Key people
Terry J. Rosen
Independent Chairman of the Board
Catherine J. Mackey
Independent Director
Scott William Morrison
Independent Director
Jeffrey L. Stein
Independent Director
Yujiro S. Hata
President, Chief Executive Officer, Director
Joshua Bleharski
Chief Financial Officer
Andres Ruiz Briseno
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
Michael A. White
Chief Scientific Officer
Darrin M. Beaupre
Chief Medical Officer
Stuart C. Dorman
Chief Commercial Officer
Theodora Ross
Chief Development Officer
M. Garret Hampton
Independent Director
Click to see more
Key facts
- Shares in issue87.81m
- EPICIDYA
- ISINUS45166A1025
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$2.78bn
- Employees145
- ExchangeNASDAQ
- IndexTR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.